TW200911302A - Pharmaceutical solutions - Google Patents
Pharmaceutical solutions Download PDFInfo
- Publication number
- TW200911302A TW200911302A TW097126552A TW97126552A TW200911302A TW 200911302 A TW200911302 A TW 200911302A TW 097126552 A TW097126552 A TW 097126552A TW 97126552 A TW97126552 A TW 97126552A TW 200911302 A TW200911302 A TW 200911302A
- Authority
- TW
- Taiwan
- Prior art keywords
- oral solution
- oral
- solution
- acid
- benzoic acid
- Prior art date
Links
- 239000003186 pharmaceutical solution Substances 0.000 title abstract description 4
- 239000003755 preservative agent Substances 0.000 claims abstract description 23
- 230000002335 preservative effect Effects 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 15
- 230000000873 masking effect Effects 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000007853 buffer solution Substances 0.000 claims abstract description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 32
- 229940100688 oral solution Drugs 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 23
- 239000005711 Benzoic acid Substances 0.000 claims description 16
- 235000010233 benzoic acid Nutrition 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 11
- 244000288157 Passiflora edulis Species 0.000 claims description 10
- 235000000370 Passiflora edulis Nutrition 0.000 claims description 10
- 235000019640 taste Nutrition 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 239000004334 sorbic acid Substances 0.000 claims description 6
- 235000010199 sorbic acid Nutrition 0.000 claims description 6
- 229940075582 sorbic acid Drugs 0.000 claims description 6
- 229960004543 anhydrous citric acid Drugs 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 235000019658 bitter taste Nutrition 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 230000009747 swallowing Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical group OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 13
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 abstract description 9
- 229960005311 telbivudine Drugs 0.000 abstract description 9
- IQFYYKKMVGJFEH-CSMHCCOUSA-N telbivudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-CSMHCCOUSA-N 0.000 abstract description 8
- 239000002904 solvent Substances 0.000 abstract description 6
- 238000004321 preservation Methods 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 241000220223 Fragaria Species 0.000 description 5
- 235000016623 Fragaria vesca Nutrition 0.000 description 5
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 229910052797 bismuth Inorganic materials 0.000 description 3
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- 150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000008369 fruit flavor Substances 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- -1 p-hydroxybenzoic acid ester Chemical class 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SMNNDVUKAKPGDD-UHFFFAOYSA-N 2-butylbenzoic acid Chemical compound CCCCC1=CC=CC=C1C(O)=O SMNNDVUKAKPGDD-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 239000005947 Dimethoate Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101100390562 Mus musculus Fen1 gene Proteins 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101100119953 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) fen gene Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- ZWLPBLYKEWSWPD-UHFFFAOYSA-N o-toluic acid Chemical compound CC1=CC=CC=C1C(O)=O ZWLPBLYKEWSWPD-UHFFFAOYSA-N 0.000 description 1
- 239000008008 oral excipient Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
200911302 九、發明說明: 【發明所屬之技術領域】 本發明係關於適用於口服之醫藥溶液,其包含P_L_胸苷/ 2 -去氧-L-胸苷(喜必服(teibivudine))、醫藥學上合適之溶 劑系統、一或多種味覺強化/遮味劑、防腐劑系統,及適 用於使藥品穩定與防腐之緩衝系統。本申請案主張2〇〇7年 7月12曰申請之Ep申請案第〇7112381 4號之優先權,因此 其内容以引用之方式全部併入本文中。 【先前技術】 在 Co// CzeM C/zew Comm⑽,第 37卷,第 4072 頁(1972)/ ·/ C/^m,35,第 4214ff頁(1992)中對 β-L-胸苷/2,_去氧_ L-胸苷(喜必服(telbivudine))進行描述。此外,在美國專利 第6,395,716號中描述β-L—胸苷/2ι_去氧_L_胸苷(喜必服 (telbivudine))用於治療B型肝炎病毒(HBV)的用途。 為向小兒族群、具有吞咽困難之個人或腎臟受損之個體 投與,因此存在一種對口服喜必服溶液之需求。 美國專利申請公開案第2002193438號中揭示一種適用於 阿立哌唑(aripiprazole)之口服溶液。然而,該等口服溶液 係用於製備微洛之抗精神分裂(anti_schiZ〇phrenic)化合物 且3有乳酸、乙酸或酒石酸(tartjc acid)。國際申請公開案 第wo 號提供一種包含加蘭他敏(gaiantamine)於 非緩衝水溶液中之口服溶液。然而,隨著時間與儲存條件 之變化,非緩衝水溶液將不會確保維持所要之?^1值,這對 於保持口服溶液防腐提出挑戰。此外,為製備口服喜必服 13I959.doc 200911302 調配物需要克服苦s之味覺、溶液穩定性及微生物生長之 難題。本文所揭*之内容出人意料意外地發現特定之㈣ 劑系統,香料類型與濃度,及溶液pH值可提供—種具有令 人愉快之味覺、穩定且微生物生長緩慢之口服喜必服: 液0 【發明内容】 本文中提供-種口服溶液,其包含有效劑量之喜必服或 其醫藥學上可接受之鹽。在一些實施例中,該溶液包含醫 藥學上合適之溶劑系統、至少一種味覺強化/遮味劑、防 腐劑系統,及緩衝系統。在另一實施例中,該味覺強化/ 遮味劑能夠遮蔽喜必服之苦味。 在上述一些實施例中,該口服溶液包含至多2〇 50 mg/mL喜必服。 在上述一些實施例中,該防腐劑系統為對羥基苯曱酸酯 或其相應鹽,山梨酸或其相應鹽,或苯甲酸或其相應鹽, 較佳為對.基苯曱酸鹽或苯甲酸。
在上述一些實施例中’該防腐劑系統之濃度範圍為〇 J mg/mL至 2.5 mg/mL。 在上述一些實施例中,該口服溶液係經1 N氫氧化納將 緩衝至約3至約5之pH值範圍内’例如緩衝至pH值約4.0。 本文中亦提供一種口服溶液,其包含20 mg/mL喜必服或 其醫藥學上可接受之鹽、1.5 mg/mL苯曱酸、〇.2 mg/mL糖 精納、1 .〇 mg/mL百香果、水及9.6 mg/mL無水檸檬酸。 本文中亦提供一種口服溶液’其包含20 mg/mL喜必服或 131959.doc 200911302 其醫藥學上可接受之鹽、K5 „^/„^苯甲酸、0.2 11^/11^糖 精納、1.0 mg/mL百香果 '水及9.6 mg/mL無水檸檬酸,其 pH值為約4.0。 本文亦提供一種用上述實施例之口服溶液治療個人之方 法。一些實施例中,該個人係選自由小兒族群、具有吞咽 困難之個人及腎臟受損之個體組成之群。 【實施方式】
在開發口服喜必服調配物期間,發現很難得到一種防腐 系統,舉例而言該溶液之pH值必須使所選擇之防腐劑具有 活性。的確,並非所有防腐劑在口服可接受之pHi下均可 提供足夠之防腐作用,尤其係針對黴菌類與酵母菌類(黑魏黴[Aspergillus niger、與台色念沬 n(Candida 之防腐作用。然而 令人驚奇地是使用一種pH值約4之含
有笨甲酸之系統’可同時達到防腐及藥品穩定之效果。 在2至9之pH值範圍内研究在5〇。古、四 凡牡〕u t冋,皿下吾必服在預調配 期間之穩定性。經證實斜於藥輪游> π釕於糸物穩定性而言,亦即從檢定 及胸嘧啶(降解產物)含量來看 9(例如pH值範圍為約4至9)。由 中微生物生長緩慢與否,所以σ 參數。 ’最佳pH值範圍為約3至 於pH值影響儲存期間溶液 服溶液之pH值為高度相關 、— 5月I初朋間,存在的難題為在保持喜 必服藥品穩定性之同時將香料人 于晋枓合併入口服溶液中。具體而 言,為遮蔽服用喜必服後之微 味見而向口服ί谷液中添加 香料。有必要識別出不干擾喜必 服樂。〇之可溶性香料。此 131959.doc 200911302 外,為得到澄清之喜必服藥品溶液,應以完全混溶/溶解 於藥品調配物中之濃度來使用該香料。 因此,本發明提供一種適用於口服之醫藥溶液,其包括 喜必服、醫藥學上合適之溶劑系統、—或多種味覺強化/ 遮味劑、防腐劑系統,及適用於同時使藥品穩定與防腐之 緩衝系統,亦即其中該溶液之pH值為約3至5,例如為約4 至5。在一實施例中,口服溶液之pH值為4 〇+/_〇.5。 〇 、本文所揭示之口服調配物中喜必服藥物之最高濃度範圍 為至多50 mg/mL。在一實施例中,在最終口服溶液中喜必 服藥物濃度為20 mg/mL。 可以0.1 mg/mL至2.5 mg/mL範圍内之濃度使用本文中所 揭示之口服調配物之防腐劑系統,諸如對羥基苯曱酸酯 (諸如包括但不限於對經基苯甲酸丁醋、對經基苯甲酸甲 自旨及對羥基苯甲酸丙醋)及其鹽,山梨酸及鹽,苯甲酸及 鹽。 υ 味覺強化/遮味劑可為濃度在〇观至〇.5%範圍内之甜味 劑諸士糖精鈉、阿斯巴甜糖(aspartame)及/或可溶香料, 諸如來自 Firmenich SA (Rue de ia Berg〜7, ch i2i7 . Meynn 2 ’瑞士)之百香果、草莓、櫻桃香料。在一實施例 . 中,調味品濃度以於或低於0.1%。在另-實施例中,使 用1 mg/mL百香果調味料。 緩衝系統可為諸如可將溶液緩衝至約4至5之pH值範圍内 ⑴如β4+/ 之#檬酸鹽緩衝液或構酸鹽緩衝液。棒樣 酸提供酸性ΡΗ值之穩定且與口服賦形劑相容之緩衝系統。 !31959.doc 200911302 檸檬酸亦提供潛在風味強化之作用及與(例如)來源於玻璃 包裝之重金屬離子聲合之作用。 醫藥學上合適之溶劑系統可為水、山梨糖醇糖漿或乙 醇。在對羥基苯甲酸酯防腐劑系統之情況中,合適之溶劑 糸統可包括(例如)丙二醇。 實例1-例示性口服調配物
將藥物溶解並穩定於經緩衝、防腐且變甜之含水系統 中°根據藥典程序(例如歐洲藥典)之步驟進行防腐效能測 試(PET)。表1與2中展示結果與調配物。 表1(調配物與PET—般結果) 調配物 組分 46-1 46-2 172-2 50-1 50-2 175-1 175-2 LDT600A 20 mg 20 mg 20 m, · 20 mg 20 mg 20 mg ?.0ηΨ 20 mg 對羥基苯曱酸甲酯 1.0 mg 1.0 mg 對羥基苯甲酸甲酯鈉 1.0 1.0 mg 對羥基苯甲酸丙酯 0.2 mg 0.2 mg 對羥基苯曱酸丙酯鈉 0-2 mg 0.2 笨甲酸 1.5 mg 1.5 mg 2.0 mg 2.0 mg 丙二醇 25 mg 25 mg . - 糖精鈉 0.2 mg 1 ^ ^ yt 0.2 mg C? 0.2 mg 0.2 mg 0.2 mg 0.2 mg 阿斯巴甜糖 0.2 mg - i : 0.2 mg 榉檬酸a緩衝液 50 mM, pH 4.0 添加到 1 mL, 奮1::1: 诗.参:縛+!+.+:; .:..ΐ 添加到 檸檬酸鹽緩衝液 50 mM,pH 5·0 添加到 1 mL 添加到 1 mL 添加到 1 mL . 添加到 1 mL 榉檬酸鹽緩衝液 50 mM, pH 6.0 添加到1 |mL 添加到 1 mL 丨 ! “ < .. . PET 未達到 未達到 達到:. 達到 未達到 未達到 達到 未達到 131959.doc 200911302 表2(調配物舆PET特異性結果)
-个,曰夂防屙糸統宁調節pH值 對喜必服的重要性。微生物限值測試資料顯示,在pH值大 於約5時,經苯甲酸防腐之口服喜必服調配物中確實存在 微生物生長。因此防腐劑苯甲酸在口服喜必服溶液中於pH 值為約4時(尤其係針對真菌類之生長)最有效。 Γ 實例2-經調味之口服調配物實例 Ο 將喜必服藥物溶解且穩定於經緩衝、防腐且調味之含水 系統中。在表3中展示—種使用苯甲酸作為單—防腐劑之 經調味之喜必服口服溶液之最終組合物。雖然僅使用單— 防腐劑’該調配物出人意料地具有至少24個月之保存期 限。而且隨著時間之推移僅觀察到表3之喜必服調配物中 之苯甲酸很少減少及藥物很少降解成胸嘧啶。& 了在保持 長期穩定性之同時亦降低在諸如小兒族群巾出現任何有宏 反應之可能性’選擇K5 mg/mL苯曱酸。表3之溶液有效二 對大腸桿菌(兄⑽)、綠膿桿菌(P.知咖_)、黑麵徵 I31959.doc • 10· 200911302 (i TWyr)及白色念珠菌(C.防腐。此外,百香果 香料在表3之喜必服調配物中保持穩定且所有經調味之溶 液(亦即櫻桃、草莓與百香果)均通過pET測試。然而,當 使用草莓香料代替百香果香料時,在5〇t下該草莓香料之 組分經過4週降解。因此認為表3之溶液具有遮蔽味覺、穩 定藥物、針對多種有機體防腐及較長保存期限之均衡特 性,而最符合要求。苯甲酸調配物亦具有接近於水之密 度,使該溶液易於與(尤其在小兒族群之情況中)投藥所需 要之飲料混合。 表3
有趣的是在加速條件下在含有20 mg/mL喜必服,兩種對 羥基苯曱酸酯防腐劑(對羥基苯甲酸甲酯與對羥基苯甲酸 〇 丙酯),防腐劑山梨酸鉀(適用於針對潛在真菌與酵母菌生 長)及草莓調味料之經調味口服溶液中,山梨酸出現顯著 且出人意外之減少(亦即50°c下經過4週後減少至約72%)。 同樣經調味之包含百香果香料之口服對羥基苯曱酸酯調配 物在50 C經過4週後顯示出較好之山梨酸檢定結果(約 90 /〇)然而,由於對羥基苯甲酸酯經調味之溶液在山梨酸 檢定中之出人意外之較差表現,需要—種以上對經基苯甲 131959.doc 200911302 會出現對羥基苯曱酸酯有害反 良味覺’因而表3之單一防腐 酸酯防腐劑,在個體中可能 應,及對經基笨甲酸醋之不 劑苯曱酸溶液為更優良之調配物。 實例3-製備口服調配物
將最少量之水加熱至60至70t,及繼而添加苯曱酸且攪 動直至完全溶解。將該苯甲酸溶液冷卻至室溫及繼而添加 各個組分且授動直至完全溶解。接著使用氫氧化鈉將阳值 調節至約3至5。最後,用水將最終體積調節至目標體積。 在上文中,藉由mg/mL醫藥組合物表示之實例丨與二中 使用之成分量陳列於表1與3中。 所 131959.doc 12·
Claims (1)
- 200911302 十、申請專利範圍: 1種口服溶液,其包含有效劑量之喜必服(tel —或 其醫藥學上可接受之鹽。 2.3求項1之口服溶液,其進-步包含醫藥學上合適之 冷J系統、至少—種味覺強化/遮味劑、防腐劑系統及緩 衝系統。 3. 如明求項2之口服溶液,其中該味覺強化/遮味劑能夠遮 蔽喜必服之苦味。 4. 如呀求項1至3中任_項之σ服溶液,其中該口 m & 含至多50 mg/mL喜必服。 5. 如清求項1至3中任一項之口服溶液,其中該口服溶液包 含至多20 mg/mL喜必服。 6. :請求項2或3之口服溶液,λ中該防腐劑系統為對經基 苯曱酸酯或其相應鹽’山梨酸或其相應鹽,或苯曱酸或 其相應鹽。 7. 如請求項2或3之口服溶液,其中該防腐劑系統之濃度範 圍為 〇· 1 mg/mL至 2.5 mg/mL。 8. —種口服溶液,其包含2〇 11^/1111喜必服或其醫藥學上可 接受之鹽、1.5 mg/mL苯甲酸、〇.2 mg/mL糖精鈉、】〇 mg/rnL百香果、水及9.6 mg/mL之無水檸檬酸。 9. 如請求項8之口服溶液,其中該口服溶液係經丨n氫氧化 鈉緩衝至約3至約5之pH值範圍内。 10. 如請求項6之口服溶液’其中該防腐劑系統為對羥基苯 131959.doc 200911302 11.如叫求項6之口服溶液其中該防腐劑系統為笨甲酸。 12’如明求項9之口服溶液,其中該口服溶液係經緩衝至PR • 口服溶液’其包含20 mg/mL喜必福或其醫藥學上可 接受之鹽、1.5 mg/mL苯甲酸、0.2 mg/mL糖精鈉、1 〇 mg/mL百香果、水及9·ό mg/mL無水檸檬酸,其或 約4.0。 值為 14. -種如請求項i至13中* 一項之口服溶液之用途, 於製造用於治療個人之藥劑。 ’、 15. 如凊求項14之料,其中該個人係選自由小兒埃群、且 有吞因困難之個人及腎臟受損之個體組成之群。 八 131959.doc 200911302 七、 指定代表圖: (一) 本案指定代表圖為:(無) (二) 本代表圖之元件符號簡單說明: 八、 本案若有化學式時,請揭示最能顯示發明特徵的化學式: (無)I 131959.doc -4 -
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07112381 | 2007-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200911302A true TW200911302A (en) | 2009-03-16 |
Family
ID=38724394
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW097126552A TW200911302A (en) | 2007-07-12 | 2008-07-11 | Pharmaceutical solutions |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8445457B2 (zh) |
| EP (1) | EP2178503A1 (zh) |
| JP (1) | JP5314014B2 (zh) |
| KR (3) | KR20140019040A (zh) |
| CN (1) | CN101686938B (zh) |
| AR (1) | AR067630A1 (zh) |
| AU (1) | AU2008274170B2 (zh) |
| BR (1) | BRPI0815562A2 (zh) |
| CA (1) | CA2693609A1 (zh) |
| CL (1) | CL2008002025A1 (zh) |
| CO (1) | CO6270204A2 (zh) |
| EC (1) | ECSP109871A (zh) |
| IL (1) | IL202961A (zh) |
| MA (1) | MA31507B1 (zh) |
| MY (1) | MY147366A (zh) |
| NZ (1) | NZ582443A (zh) |
| PE (2) | PE20090476A1 (zh) |
| RU (1) | RU2493826C2 (zh) |
| TN (1) | TN2010000008A1 (zh) |
| TW (1) | TW200911302A (zh) |
| WO (1) | WO2009007426A1 (zh) |
| ZA (1) | ZA200908993B (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2712358T1 (sl) | 2011-05-13 | 2017-03-31 | Array Biopharma, Inc. | Spojine pirolidinil sečnine, pirolidinil tiosečnine in pirolidinil gvanidina kot inhibitorji kinaze trka |
| WO2014059363A1 (en) * | 2012-10-11 | 2014-04-17 | Antrim Pharmaceuticals Llc | Oral solution formulations of aripiprazole |
| PT3154959T (pt) | 2014-05-15 | 2019-09-24 | Array Biopharma Inc | 1-((3s,4r)-4-(3-fluorofenil)-1-(2-metoxietil)-pirrolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)ureia como inibidor da cinase trka |
| EP3288562B1 (en) * | 2015-04-26 | 2022-03-16 | MacKay Memorial Hospital | Method for improving kidney and/or heart function in patients with kidney disease |
| CN107550866A (zh) * | 2016-06-30 | 2018-01-09 | 康普药业股份有限公司 | 一种替比夫定制剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5856364A (en) | 1991-03-01 | 1999-01-05 | Warner Lambert Company | Therapeutic antiviral-wound healing compositions and methods for preparing and using same |
| WO1999016447A1 (fr) | 1997-09-26 | 1999-04-08 | Wakamoto Pharmaceutical Co., Ltd. | Preparation aqueuse contenant un agent antiviral a ossature purine ou pyrimidine |
| DE19817264A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Neue Dihydropyrimidine |
| DE19817265A1 (de) | 1998-04-18 | 1999-10-21 | Bayer Ag | Verwendung von Dihydropyrimidinen als Arzneimittel und neue Stoffe |
| AR037131A1 (es) | 2001-10-31 | 2004-10-20 | Schering Corp | Formulaciones de jarabe de ribavirina |
| TWI244393B (en) * | 2002-08-06 | 2005-12-01 | Idenix Pharmaceuticals Inc | Crystalline and amorphous forms of beta-L-2'-deoxythymidine |
| WO2006130217A2 (en) | 2005-04-01 | 2006-12-07 | The Regents Of The University Of California | Substituted phosphate esters of nucleoside phosphonates |
-
2008
- 2008-07-10 BR BRPI0815562-3A2A patent/BRPI0815562A2/pt not_active IP Right Cessation
- 2008-07-10 RU RU2010104395/15A patent/RU2493826C2/ru not_active IP Right Cessation
- 2008-07-10 KR KR1020147002720A patent/KR20140019040A/ko not_active Ceased
- 2008-07-10 AR ARP080102959A patent/AR067630A1/es unknown
- 2008-07-10 AU AU2008274170A patent/AU2008274170B2/en not_active Ceased
- 2008-07-10 MY MYPI20095510A patent/MY147366A/en unknown
- 2008-07-10 JP JP2010515512A patent/JP5314014B2/ja not_active Expired - Fee Related
- 2008-07-10 CA CA2693609A patent/CA2693609A1/en not_active Abandoned
- 2008-07-10 US US12/667,975 patent/US8445457B2/en not_active Expired - Fee Related
- 2008-07-10 NZ NZ582443A patent/NZ582443A/en not_active IP Right Cessation
- 2008-07-10 CN CN2008800241250A patent/CN101686938B/zh active Active
- 2008-07-10 PE PE2008001158A patent/PE20090476A1/es not_active Application Discontinuation
- 2008-07-10 PE PE2012002012A patent/PE20130180A1/es not_active Application Discontinuation
- 2008-07-10 WO PCT/EP2008/059016 patent/WO2009007426A1/en not_active Ceased
- 2008-07-10 KR KR1020107000530A patent/KR20100029829A/ko not_active Ceased
- 2008-07-10 EP EP08774979A patent/EP2178503A1/en not_active Withdrawn
- 2008-07-10 KR KR1020127016214A patent/KR20120078754A/ko not_active Withdrawn
- 2008-07-11 TW TW097126552A patent/TW200911302A/zh unknown
- 2008-07-11 CL CL2008002025A patent/CL2008002025A1/es unknown
-
2009
- 2009-12-17 ZA ZA200908993A patent/ZA200908993B/xx unknown
- 2009-12-24 IL IL202961A patent/IL202961A/en not_active IP Right Cessation
-
2010
- 2010-01-07 MA MA32485A patent/MA31507B1/fr unknown
- 2010-01-07 TN TNP2010000008A patent/TN2010000008A1/fr unknown
- 2010-01-12 EC EC2010009871A patent/ECSP109871A/es unknown
- 2010-01-12 CO CO10002343A patent/CO6270204A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CO6270204A2 (es) | 2011-04-20 |
| US20100197629A1 (en) | 2010-08-05 |
| ZA200908993B (en) | 2010-09-29 |
| WO2009007426A1 (en) | 2009-01-15 |
| BRPI0815562A2 (pt) | 2015-02-18 |
| ECSP109871A (es) | 2010-02-26 |
| AU2008274170A1 (en) | 2009-01-15 |
| MA31507B1 (fr) | 2010-07-01 |
| CN101686938B (zh) | 2012-09-05 |
| CN101686938A (zh) | 2010-03-31 |
| TN2010000008A1 (en) | 2011-09-26 |
| PE20130180A1 (es) | 2013-03-06 |
| KR20120078754A (ko) | 2012-07-10 |
| NZ582443A (en) | 2011-04-29 |
| KR20140019040A (ko) | 2014-02-13 |
| CL2008002025A1 (es) | 2009-05-08 |
| IL202961A (en) | 2013-10-31 |
| JP5314014B2 (ja) | 2013-10-16 |
| EP2178503A1 (en) | 2010-04-28 |
| JP2010533146A (ja) | 2010-10-21 |
| RU2493826C2 (ru) | 2013-09-27 |
| KR20100029829A (ko) | 2010-03-17 |
| AR067630A1 (es) | 2009-10-21 |
| RU2010104395A (ru) | 2011-08-20 |
| US8445457B2 (en) | 2013-05-21 |
| PE20090476A1 (es) | 2009-05-12 |
| AU2008274170B2 (en) | 2011-06-09 |
| MY147366A (en) | 2012-11-30 |
| CA2693609A1 (en) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102159184B (zh) | 含有对乙酰氨基酚的液体药物制剂 | |
| KR100841893B1 (ko) | 프레가발린 조성물 | |
| CN103501773A (zh) | 用于口服给予的他喷他多含水药物制剂 | |
| JP6347891B2 (ja) | 液状医薬組成物 | |
| TW200911302A (en) | Pharmaceutical solutions | |
| CN103932979A (zh) | 包含聚乙二醇和电解质的溶液 | |
| JP6410814B2 (ja) | フェキソフェナジンを含む経口投与用液体医薬組成物 | |
| JP7254101B2 (ja) | 複数回使用のトラセミド組成物 | |
| CN1582155A (zh) | 利巴韦林糖浆制剂 | |
| JP7642091B2 (ja) | L-セリン又はその薬学的に許容される塩の液体製剤及びそれを調製するための方法 | |
| TWI304339B (en) | Pharmaceutical composition of piperazine derivatives | |
| WO2017212409A1 (en) | A novel pharmaceutical composition of a lipid lowering compound | |
| JP4388743B2 (ja) | 水溶性内服液剤 | |
| JP6794758B2 (ja) | 経口液体医薬組成物 | |
| JPH08333268A (ja) | カンゾウの抽出物を配合した安定な液剤 | |
| JP2003095933A (ja) | 内服液剤組成物 | |
| JP2004269363A (ja) | アセトアミノフェンを含有する安定な水性医薬組成物 | |
| JP2025083800A (ja) | ピモベンダンを含有する経口フィルム製剤 | |
| JP2008088116A (ja) | 水性内服液剤組成物 | |
| TW200418472A (en) | Dry syrup preparation of procaterol |